Key result
PLA2G10 T-512C polymorphism is associated with fewer recurrent cardiovascular events, but R38C shows no CAD effect.
Cohort
Answers are grounded in this paper and cite their sources.
Prospective study reveals PLA2G10 gene variant association with reduced recurrent cardiovascular events, indicating secreted phospholipase A2 involvement in vascular inflammation.
Among secreted phospholipases A2 (sPLA2s), human group X sPLA2 (hGX sPLA2) is emerging as a novel attractive therapeutic target due to its implication in inflammatory diseases. To elucidate whether hGX sPLA2 plays a causative role in coronary artery disease (CAD), we screened the human PLA2G10 gene to identify polymorphisms and possible associations with CAD end-points in a prospective study, AtheroGene. We identified eight polymorphisms, among which, one non-synonymous polymorphism R38C in the propeptide region of the sPLA2. The T-512C polymorphism located in the 5' untranslated region was associated with a decreased risk of recurrent cardiovascular events during follow-up. The functional analysis of the R38C polymorphism showed that it leads to a profound change in expression and activity of hGX sPLA2, although there was no detectable impact on CAD risk. Due to the potential role of hGX sPLA2 in inflammatory processes, these polymorphisms should be investigated in other inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Gora et al. (2009) conducted a cohort in Coronary artery disease. PLA2G10 gene polymorphisms (including T-512C and R38C) vs. Wild-type alleles was evaluated on Recurrent cardiovascular events and CAD risk. The PLA2G10 T-512C polymorphism was associated with decreased recurrent cardiovascular events, whereas the functional R38C polymorphism had no detectable impact on CAD risk.
Synapse has enriched 10 related papers. Consider them for comparative context: